Alumis Inc. (NASDAQ:ALMS) Director Alan Colowick Buys 16,104 Shares

Alumis Inc. (NASDAQ:ALMS) Director Alan Colowick acquired 16,104 shares of the firm’s stock in a transaction dated Tuesday, April 1st. The shares were purchased at an average cost of $6.97 per share, for a total transaction of $112,244.88. Following the completion of the acquisition, the director now directly owns 16,104 shares in the company, valued at approximately $112,244.88. This represents a ? increase in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through this link.

Alumis Stock Down 13.2 %

ALMS stock opened at $8.54 on Friday. Alumis Inc. has a 12 month low of $3.18 and a 12 month high of $13.53. The company has a 50-day moving average price of $5.46 and a 200 day moving average price of $8.24.

Wall Street Analysts Forecast Growth

A number of equities research analysts recently issued reports on the stock. HC Wainwright reaffirmed a “buy” rating and set a $15.00 price target on shares of Alumis in a research note on Wednesday, March 26th. Oppenheimer started coverage on shares of Alumis in a research report on Thursday, January 30th. They set an “outperform” rating and a $32.00 target price on the stock. Finally, Cantor Fitzgerald reiterated an “overweight” rating on shares of Alumis in a research report on Thursday, March 20th. Seven equities research analysts have rated the stock with a buy rating and two have given a strong buy rating to the company. According to MarketBeat, Alumis has an average rating of “Buy” and an average price target of $26.00.

Institutional Trading of Alumis

Several institutional investors have recently added to or reduced their stakes in the company. Tang Capital Management LLC raised its holdings in shares of Alumis by 40.6% in the fourth quarter. Tang Capital Management LLC now owns 600,000 shares of the company’s stock worth $4,716,000 after buying an additional 173,406 shares during the period. Foresite Capital Management V LLC increased its stake in Alumis by 3.5% in the fourth quarter. Foresite Capital Management V LLC now owns 5,779,348 shares of the company’s stock worth $45,426,000 after purchasing an additional 194,459 shares during the period. BNP Paribas Financial Markets lifted its position in shares of Alumis by 1,257.0% during the fourth quarter. BNP Paribas Financial Markets now owns 34,835 shares of the company’s stock worth $274,000 after purchasing an additional 32,268 shares during the last quarter. Ally Bridge Group NY LLC boosted its stake in shares of Alumis by 6.4% during the fourth quarter. Ally Bridge Group NY LLC now owns 445,259 shares of the company’s stock valued at $3,500,000 after purchasing an additional 26,843 shares during the period. Finally, Foresite Capital Management VI LLC bought a new position in shares of Alumis in the fourth quarter worth about $33,033,000.

Alumis Company Profile

Our mission is to significantly improve the lives of patients by replacing broad immunosuppression with targeted therapies. Our name, Alumis, captures our mission to enlighten immunology, and is inspired by the words “allumer”-French for illuminate-and “immunis”-Latin for the immune system. We are a clinical stage biopharmaceutical company with an initial focus on developing our two Tyrosine Kinase 2 (TYK2) inhibitors: ESK-001, a second-generation inhibitor that we are developing to maximize target inhibition and optimize tolerability, and A-005, a central nervous system (CNS) penetrant molecule.